Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IDYA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Darovasertib (IDE196) | Uveal Melanoma | Phase 3 · NCT07015190 | Recruiting |
| PD1 Inhibitor | Neoplasms, Colorectal | Phase 1/2 · NCT06710847 | Active not recruiting |
| Anti-DLL3 Antibody-drug Conjugate IDE849 | Small-cell Lung Cancer | Phase 1/2 · NCT07174583 | Recruiting |
| PARG Inhibitor IDE161 | Small-cell Lung Cancer | Phase 1/2 · NCT07174583 | Recruiting |
| WRN Inhibitor GSK4418959 | Neoplasms, Colorectal | Phase 1/2 · NCT06710847 | Active not recruiting |
| Anti-B7-H3/Anti-PTK7-TOP1i Bispecific… | Esophageal Squamous Cell Carcinoma | Phase 1 · NCT07503808 | Recruiting |
| Tuvutromstat (IDE397) | Solid Tumor | Phase 1 · NCT04794699 | Active not recruiting |
| KAT6/KAT7 Inhibitor IDE574 | Cancer | Phase 1 · NCT07540572 | Recruiting |
| PRMT5 Inhibitor IDE892 | NSCLC Adenocarcinoma | Phase 1 · NCT07277413 | Recruiting |
Also used in these trials (approved or third-party drugs, not IDYA's own candidates): Pembrolizumab, Crizotinib, Dacarbazine, Nivolumab, Ipilimumab, Carboplatin, Durvalumab, Binimetinib, Fulvestrant, Sacituzumab Govitecan.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IDYA holds $1.2B in cash and short-term investments (as of Sep 30, 2026) and burns about $90.8M/quarter from operations, an estimated runway of 38 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 32 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IDYA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | Institution (13G, 5%+) | 7,265,253 | 7.51% | 2026-03-31 |
| Capital Research Global Investors | Institution (13G, 5%+) | 5,279,675 | 5.46% | 2025-12-31 |
| Baker Bros. Advisors LP | Institution (13G, 5%+) | 5,010,030 | 5.18% | 2026-06-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 4,834,771 | 5.00% | 2026-06-30 |
| Yujiro S Hata President and CEO, Director · +1.41M options |
Insider | 690,695 | 0.71% | 2026-10-06 |
| Jason Throne Chief Legal Officer · +42,546 options |
Insider | 63,484 | 0.07% | 2024-06-27 |
| Jeffrey Stein Director · +56,200 options |
Insider | 57,644 | 0.06% | 2026-03-02 |
| Briseno Andres Ruiz Chief Accounting Officer · +174,200 options |
Insider | 26,466 | 0.03% | 2026-07-07 |
| Douglas B. Snyder SVP, General Counsel · +303,000 options |
Insider | 2,080 | 0.00% | 2026-01-30 |
Share count 96,694,575 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IDYA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →